替格瑞洛在冠脉介入治疗后的治疗效果及安全性临床效果观察  

Clinical Observation on the Therapeutic Effect and Safety of Tigrilol after Coronary Intervention

作　　者：牛卫洲 李江科 陈少军[1] NIU Wei-zhou;LI Jiang-ke;CHEN Shao-jun(Department of Cardiology,Huairou District Traditional Chinese Medicine Hospital,Beijing,101400 China)

机构地区：[1]北京市怀柔区中医医院心血管科,北京101400

出　　处：《世界复合医学》2020年第2期183-185,共3页World Journal of Complex Medicine

摘　　要：目的探讨接受冠脉介入治疗的患者临床应用替格瑞洛的治疗效果及其临床安全性。方法择取在该院接受冠脉介入治疗的144例心绞痛患者,选择时间段为2018年1月—2019年1月,所有患者均为不稳定型,采用随机数字表法将患者划分为平行组和安全组,每组各72例。所有患者均在接受常规治疗后接受氯吡格雷或替格瑞洛治疗,平行组患者接受氯吡格雷治疗,安全组患者接受替格瑞洛治疗,对比两组患者的血栓情况、血流情况及不良事件情况(脑卒中、心源性猝死、心绞痛再发、心梗再发)和药物不良反应(呼吸困难、出血)。结果安全组患者的血栓情况2.78%、血流情况9.72%及不良事件情况2.78%(脑卒中、心源性猝死、心绞痛再发、心梗再发)均优于平行组患者,组间数据差异有统计学意义(χ2=6.849、5.857、10.125,P=0.009、0.016、0.002<0.05)。安全组患者的呼吸困难、出血等药物不良反应率与平行组患者的呼吸困难、出血等药物不良反应率,组间数据差异无统计学意义(P>0.05)。结论针对接受冠脉介入治疗的患者临床给予替格瑞洛治疗,相较于氯吡格雷治疗能够更好地改善患者的血栓情况和血流情况,减少脑卒中、心源性猝死、心绞痛再发、心梗再发等不良事件的发生率,且药物不良反应与氯吡格雷一致,具有一定的安全性,具有重要的临床意义,值得推广和应用。Objective To investigate the clinical efficacy and clinical safety of ticagrelor in patients undergoing coronary intervention.Methods A total of 144 patients with angina pectoris who underwent coronary intervention in our hospital were enrolled.The patients were selected from January 2018 to January 2019.All patients were unstable.The patients were divided into parallels by random number table.Group and safety groups,72 in each group.All patients received clopidogrel or ticagrelor after routine treatment.Patients in the parallel group received clopidogrel.Patients in the safety group received ticagrelor.The thrombus and blood flow were compared between the two groups.Adverse events(stroke,sudden cardiac death,recurrent angina,recurrent myocardial infarction)and adverse drug reactions(dyspnea,bleeding).Results The thrombus status in the safety group was 2.78%,the blood flow status was 9.72%,and the adverse event status was 2.78%(stroke,sudden cardiac death,recurrence of angina pectoris,and recurrence of myocardial infarction)were better than those in the parallel group.Statistical significance(χ2=6.849,5.857,10.125,P=0.009,0.016,0.002<0.05).The rates of adverse drug reactions such as dyspnea and bleeding in the safety group were not statistically different from those in the parallel group(P>0.05).Conclusion The clinical treatment of ticagrelor in patients undergoing coronary intervention is better than clopidogrel in improving thrombus and blood flow,reducing stroke,sudden cardiac death,and angina.The incidence of adverse events such as hair loss and myocardial infarction,and the adverse drug reaction are consistent with clopidogrel.It has certain safety and has important clinical significance,which is worthy of promotion and application.

关 键 词：替格瑞洛 冠脉介入治疗 治疗效果 安全性 临床效果 

分 类 号：R541.4[医药卫生—心血管疾病]